New drug for tardive dyskinesia:
C i.e. ValbenazineRef: https://www. accessdata. fda. gov/drugsatfda_docs/label/2017/209241lbl. pdfExplanation:Valbenazine:Vesicular monoamine transporter 2 (VMAT2) inhibitor.Specifically indicated for the treatment of adults with tardive dyskinesia.Supplied as a capsule for oral administration.Tetrabenazine:Centrally-acting dopamine depletor.Selective and reversible.Used in chorea associated with Huntington's disease.Deutetrabenazine: (Approved in April 2017)It is a vesicular monoamine transporter 2 (VMAT2) inhibitor.Specifically indicated for the treatment of chorea associated with Huntington's disease.Supplied as a tablet for oral administration.Safinamide:MAO B inhibitor.Approved for treatment of on off phenomena seen with levodopa in parkinson's disease.
Safinamide
Tetrabenazine
Valbenazine
Deutetrabenazine
C.N.S